• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Fusion Pharmaceuticals Acquires IPN-1087

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific

    Q BioMed Inks Strontium89 Supply Pact

    PCI Pharma Services Appoints SVP, CFO
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WuXi AppTec Completes OXGENE Acquisition

    Celonic Group Announces Plans for New Facility in Switzerland

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production

    Arcline Investment Acquires ChargePoint Technology
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reshaping the Pharmaceutical Supply Chain

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific

    WuXi AppTec Completes OXGENE Acquisition

    Live Webinar - Formulation Strategies for Poorly Soluble Molecules

    Celonic Group Announces Plans for New Facility in Switzerland
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Adare Pharma Solutions

    Federal Equipment Company

    Cytovance Biologics

    Reed-Lane
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    Alcami

    Syngene

    Reed-Lane

    Adare Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Beyond the Boundaries

    New capsule types resolve emerging formulation needs.

    Beyond the Boundaries
    Photo courtesy of ACG Capsules.
    Related CONTENT
    • Phlow Corp. and USP Form Alliance
    • Cryoport Launches ESG Program
    • Solid Dose Market Trends
    • Manufacturing Equipment Trends
    • AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    Sven Stegemann, ACG Capsules09.09.20
    Pharma delivery methods, like medicines themselves, have become increasingly customized. This holds true even for one of the most common formats: the two-piece capsule.

    There is good reason that capsules have been go-to drug delivery solutions for so long. In addition to the inherent versatility of typical two-piece capsules, a standard ingredient—gelatin—provides favorable attributes such as high mechanical robustness, fast aqueous dissolution, taste and odor masking, bi-chromatic differentiation and ease of swallowing. But as both global needs and pharma products themselves evolve, new challenges have arisen; these obstacles span a spectrum from access to medicines in developing countries to sophisticated drug products treating previously unaddressed conditions.

    Meeting these modern needs means incorporating innovative two-piece capsules with specific characteristics or functionalities, while maintaining the key features of versatility and commercial viability for which the standard gelatin capsule has become known. Typically, these particulars are derived from a drug’s Target Product Profile (TPP), which defines the crucial aspects a medicine must achieve.1 A variety of factors (Table 1) must be considered, including a medicine’s molecular makeup and therapeutic components (or combinations thereof), preferred delivery form(s), targeted patient populations, specific markets and regions, technology accessibility and, of course, overall manufacturing costs.


    Table 1. Target Poduct Profile (TPP) considerations relevant to capsule and formation.

    Formulation and process design
    Defining a drug’s TPP is a mission statement and roadmap rolled into one: it allows for a clear-eyed, prioritized view of the medicine’s overarching goals and, with these data points logically laid out, helps forge a detailed plan toward its formulation, process and product development. The multifactorial nature of drug development requires a systematic approach that gives added emphasis on required attributes over requested ones—a delineation between “must have” and “want to have.”

    This approach is the most efficient route to developing a product that meets all required elements and most (and potentially even all) of the desired ones. A well-executed TPP process offers an evidence-based, non-biased assessment of formulation strategies and delivery possibilities.

    Always, the process must include a formal risk assessment to identify known or predicted critical material attributes or process parameters that could impact its performance consistency or manufacturability. These critical material attributes and process parameters are evaluated via experiments, simulation and/or predictive modeling to assure ultimate viability.2,3

    A proper TPP also prevents pharma companies from “overdoing it” from a formulation perspective, preventing the unnecessary use of extraneous excipients and avoidable additional processing steps. Like most production strategies, pharma product development has a “Goldilocks Zone” that, once discovered, prevents over-engineering and the unnecessary complexities and costs associated with it.

    In an increasingly competitive market, formulation and process simplicity can be key to widespread product adoption by key target population segments, as it becomes a determining factor in manufacturing efficiency, effectiveness and cost mitigation.4,5

    Evolving capsule technology
    Within this overarching discussion on defining a drug’s TPP, it becomes clear that one way to work toward streamlined, cost-effective production for a broad array of products is to favor versatile delivery technology platforms that meet formulation needs while addressing existing and emerging industry issues. The new challenges arising from shorter development timelines (including drugs gaining expedited designations such as Fast Track, Breakthrough, Priority Review, and Accelerated Approval), pediatric formulations, therapy personalization, demographic changes, decentralization of manufacturing, cost containment and sustainability require, to varying degrees, advanced excipients, formulations, processes and flexible dosing. 

    Hydroxypropyl methycellulose, also called Hypromellose or HPMC, is a cellulose-based semisynthetic polymer established as a pharmaceutical excipient in the early 1970s. Four types of HPMC—suitable for applications ranging from a film forming agent in coatings to a matrix former for modified release tablets—are detailed in pharmaceutical monographs6 HPMC also is considered a crystallization inhibitor, which helps increase solubility and bioavailability for poorly soluble low ionized drugs containing a neutral amine group.7 Additional benefits of HPMC are its largely temperature- and humidity-independent viscoelastic properties, and its relative inertness against reactive chemicals.8

    Extensive research and technology development have been undertaken to introduce capsules that marry HPMC’s unique material properties with the advantages of common two-piece capsules. These include a set of HPMC capsules created through an innovative thermogelation process that continues to broaden the range of functionalities and applications of capsules in drug development and manufacturing. The thermogelation technology utilizes the reversible sol-gel transformation of HPMC upon heating to 50-90° C to form pure HPMC capsules.

    The result is a capsule that allows specifically desired product characteristics, as defined in a drug’s TPP, to be integrated and delivered. This flexible functionality can help avoid the need for intensive formulation and process development programs prompted by the addition of multiple excipients and processing steps—which, of course, in turn lead to complex manufacturing processes, added risks and increased costs.

    Key functionalities of thermogelated HPMC capsules
    Thermogelated HPMC capsules, including ACGcaps H+ from my company, ACG Capsules, are characterized by a homogeneous, smooth surface structure with glasslike transparency. As with common two-piece capsules, colorants can be added to produce colored-yet-transparent or opaque capsules that, in turn, can be further customized by mono- and/or bi-chromatic printing.

    This flexibility allows varying dose strengths of drug combinations in fixed dose combination products, and products with multiple release profiles, yet being distinctively differentiated within an overarching brand. This clearly distinguishes differing drug products for reduced medication errors and increased safety, which is especially important with instances of polypharmacy. In addition, the glasslike transparency of the capsules allows inhalation therapy patients to verify both the presence and release of the drug during administration.  

    Using standard dissolution tests (e.g. USP type II apparatus with sinker) and acetaminophen as a model drug formulation, the capsule ruptures and releases its contents within 5-10 minutes in all media—pH 1.2 - 0.1N HCl; pH 4.5 - acetate buffer; pH 6.8 - phosphate buffer (see Figure 1).


    Figure 1. Dissolution profiles of thermogelated HPMC capsules (ACGcaps H+) filled with acetaminophen in different media (USP Appartatus 2 (Paddle) with sinker at 50 rpm; ACG caps H+ capsule size 0 transparent filled with 464 mg acetaminophen (paracetamol) granules composed of (90% acetaminophen; 1% Mag Stearate; 3% PVP; 2% Croscarmellose sodium and 4% Lactose).

    The dissolution profiles align with pharmacopeial requirements for immediate release oral formulations. However, for weak acid or weak base drugs with poor aqueous solubility, such as dabrafenib, HPMC capsules may act as a crystallization inhibitor and increase bioavailability.9 For such BCS class 2 compounds, the thermogelated HPMC capsules provide superior dissolution and bio-enhancement functionality, which also might contribute to a reduced inter- and intra-subject variability.

    For a variety of reasons, multi-particulates like pellets, mini-tablets or granules are increasingly being explored as treatment options for special patient populations. Here, factors include increased palatability and swallowability, individual dosing according to body weight, body surface, age or kidney function.10,11 Modified release (e.g. enteric formulations) are preferred in oral forms due to gradual and predictable release from the stomach.12,13 Many of these multi-particulate formulations are designed to protect acid- and moisture-sensitive drugs, and to ensure quick dissolution in the duodenum through hydrophilic excipients.

    To achieve sufficient stability for moisture-sensitive products, headspace humidity in two-piece capsules needs to be within a defined range. The capsule moisture (LOD) of HPMC capsules is directly correlated with headspace humidity, and is adjustable without impacting the mechanical and elastic properties of the capsule or its dissolution. For example, if product manufacturing conditions of 22°C and 20% RH are required, HPMC capsules provide the respective design space for robust product performance.

    Likewise, interactive powder blends or engineered particles for dry powder inhalation require specific headspace humidity; HPMC capsules allow for easy adjustment without negatively impacting the performance of the capsules in the diverse inhalation devices.14

    Advanced drug delivery technologies targeting specific areas in the GI tract (e.g. colonic delivery), and emerging sensitive therapeutics (e.g. live microbiota) require oral dosage forms that do not use compression, and release the therapeutic agent within a specific gastric environment quickly. The coating of filled capsules has demonstrated to be highly suitable for targeted delivery to the gastrointestinal tract. Aqueous coating compositions have demonstrated favorable adhesion characteristics on HPMC and, as such, on HPMC capsules. By using different types of coating polymers, and varying the coating thickness, in-vivo release could be targeted to different areas within the gastrointestinal tract.15

    Conclusion
    The two-piece capsule is an established dosage form with proven viability for a diverse range of compounds, formulations, drug delivery technologies and applications. Because a capsule product can be efficiently manufactured in just two straightforward steps (blending & filling), encapsulation is used from early product development through full-scale commercial manufacturing due to its global availability.

    Innovation and evolving technology continue to provide new and improved therapeutic options for acute, chronic and life-threatening diseases, and relevant new drug delivery technologies to enable their therapeutic efficacy and site-specific delivery. The growing demand for affordable medicines from low- and middle-income countries presents a global responsibility to produce high-quality medicines more efficiently, cost effectively and locally.

    To meet these emerging requirements, the inherent advantages of capsules can be introduced to a variety of pharma products by developing capsules with specific properties. HPMC capsules manufactured by a thermogelation process are fast-dissolving delivery vehicles.

    As such, HPMC capsules are highly resistant across environmental temperature and moisture conditions. Moreover, they can be adjusted to specific moisture or headspace humidity while maintaining critical elastic properties even under stress (e.g. piercing or shearing). For products sensitive to compression, liquid or semi-solids, or life microbiota requiring targeted delivery in the gastrointestinal tract, the capsules can be easily coated with different solutions at varying thicknesses. Using standard capsule filling equipment at known machineability performance, HPMC capsules can help simplify both formulation and process procedures, each of which are crucial factors in increasing cost efficiency in pharmaceutical manufacturing. 

    References
    1. ICH Q8 R2 Pharmaceutical Development Guideline (2009)
    2. Stranzinger et al Int J Pharm: X (2019) 1: 100004
    3. Madlmeier et al Int J Pharm (2019) 567:118441
    4. Cogdill et al J Pharm Innov (2007) 2:38–50
    5. Friedli et al  J Pharm Innov (2010) 5:181–192
    6. HPMC Monograph - USP 41, Pharm Eur 10th edition
    7. Zarmpi et al AAPS J (2020) 22:49
    8. Handbook of pharmaceutical excipients. Eds: Rowe RC, Sheskey PJ, Quinn ME. pp. 326-329 (2009)
    9. Ouellet et al J Pharm Sci (2013) 102(9): 3100–3109
    10. Klingmann et al J Pediatr (2012) 163:1728-32
    11. Klingmann et al J Pediatr (2015) 167:893-6
    12. Digenis et al J Clin Pharmacol (1990) 30, 621-631
    13. Abrahamsson et al Int J Pharm (1996) 140, 229-235
    14. Geller et al J Aerosol Med Pulmo Drug Del (2011) 24(4):175-182
    15. Cole et al Int J Pharm (2002) 231: 83-95


    Prof. Dr. Sven Stegeman is Global Head of Scientific Business Development at ACG Capsules, and a professor of patient centric drug design and manufacturing at the Graz University of Technology, Austria. ACG Group is an integrated pharma manufacturing solutions company whose divisions include Capsules, Films & Foils, Engineering, and Inspection.
    Suggested For You
    Phlow Corp. and USP Form Alliance Phlow Corp. and USP Form Alliance
    Cryoport Launches ESG Program Cryoport Launches ESG Program
    Solid Dose Market Trends Solid Dose Market Trends
    Manufacturing Equipment Trends Manufacturing Equipment Trends
    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    Vetter continues its successful performance at the 2021 CMO Leadership Awards Vetter continues its successful performance at the 2021 CMO Leadership Awards
    FUJIFILM Diosynth Hosts UK PM at COVID Vax Mfg. Site FUJIFILM Diosynth Hosts UK PM at COVID Vax Mfg. Site
    Pfizer, BioNTech to Supply the U.S. with 100mn Additional Doses of COVID-19 Vaccine Pfizer, BioNTech to Supply the U.S. with 100mn Additional Doses of COVID-19 Vaccine
    Anova Enterprises Acquires Corlexia Clinical Services Anova Enterprises Acquires Corlexia Clinical Services
    Thermo Fisher, JW Therapeutics Form CAR-T Partnership in China Thermo Fisher, JW Therapeutics Form CAR-T Partnership in China
    Catalent, Trizell Enter Cell Therapy Deal Catalent, Trizell Enter Cell Therapy Deal
    Immunome, Abzena Enter COVID-19 Antibody Cocktail Agreement Immunome, Abzena Enter COVID-19 Antibody Cocktail Agreement
    Syntegon Validates First AI-equipped Visual Inspection System Syntegon Validates First AI-equipped Visual Inspection System
    UK Secures 40M Doses of Valneva COVID-19 Vax UK Secures 40M Doses of Valneva COVID-19 Vax
    Recipharm, Medspray Launch Resyca JV Recipharm, Medspray Launch Resyca JV

    Related Features

    • Solid Dosage/Creams/Ointments
      High Drug Loading Amorphous Solid Dispersions

      High Drug Loading Amorphous Solid Dispersions

      A Novel Tablet Architecture for Amorphous Solid Dispersions to Achieve High Drug Loadings
      Deanna Mudie and Aaron Stewart, Lonza 01.27.21

    • Parenterals
      Parenteral Drug Delivery Trends

      Parenteral Drug Delivery Trends

      A Q&A with Lubrizol Life Science Health’s CDMO Division President, Rob Lee.
      Kristin Brooks, Managing Editor, Contract Pharma 01.27.21

    • Selecting the Right Outsourcing Model for Emerging Biotech

      Selecting the Right Outsourcing Model for Emerging Biotech

      Flexible outsourcing models help drive quality, control costs and enable better efficiencies and faster delivery.
      Timothy King and Elisha Talley-Roithner, PPD 01.27.21


    • Drug Delivery
      Inhaled Drug Delivery Technology

      Inhaled Drug Delivery Technology

      The success of any new inhaled medicine relies in a large part on the correct combination of formulation and device technology being chosen for its delivery.
      Dr. Sandy Munro, Vice President – Pharmaceutical Development, Vectura 01.27.21

    • Biologics, Proteins, Vaccines
      The Future of Biologics: Accelerating Production, Reducing Costs

      The Future of Biologics: Accelerating Production, Reducing Costs

      Yeast-based gene expression offers pharma the yield and efficiencies it needs to make pandemic-stopping vaccines faster and more economical.
      Mark Emalfarb, Dyadic 01.27.21

    • Analytical Services | Information Technology | Laboratory Testing
      Business Intelligence For (and From) the Lab

      Business Intelligence For (and From) the Lab

      How a digital ecosystem can harness the most data-rich environment in the CDMO.
      Bob Voelkner, VP Sales and Marketing, LabVantage 01.27.21


    • Communicating Your Contracting Priorities to Your Drug Company Customers

      Communicating Your Contracting Priorities to Your Drug Company Customers

      A discussion with Perrigo’s senior legal counsel, Susan Fyan, about issues that arise in very fact-specific contract negotiations between CDMOs and sponsors.
      Stephen Sayre, Dykema 01.27.21

    • COVID-19 Impact Report

      COVID-19 Impact Report

      Leaders across the pharmaceutical contract services industry reflect on the impact of COVID-19 in 2020, and what to expect in 2021.
      Tim Wright, Editor, Contract Pharma 01.27.21

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to “normalcy.”
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Attorneys - Axinn, Veltrop & Harkrider LLP 01.27.21


    • Excipients
      Bye-Bye China?

      Bye-Bye China?

      Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
      Michele Jermini and Enrico Polastro 11.17.20

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • The Single-Use Mixing Landscape: Evaluating Your Options

      The Single-Use Mixing Landscape: Evaluating Your Options

      Adoption of single-use technologies has increased markedly in recent years and will continue to grow.
      Mark A. Sitcoske, Founder & CEO, High Purity New England 11.17.20

    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      Lonza’s Director of Commercial Development, Sean Diver, was recently named President of DCAT.
      Tim Wright, Editor, Contract Pharma 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    Trending
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Bormioli Opens New Glass Research Center
    • Arcline Investment Acquires ChargePoint Technology
    • WuXi AppTec Completes OXGENE Acquisition
    Breaking News
    • Fusion Pharmaceuticals Acquires IPN-1087
    • Strata Oncology Unveils Strata PATH Trial
    • Alimentiv Acquires McDougall Scientific
    • Q BioMed Inks Strontium89 Supply Pact
    • PCI Pharma Services Appoints SVP, CFO
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Low Levels of Vitamin D and Calcium Linked to COVID-19 Severity
    Probiotic Evidenced to Assist Digestive Recovery from a Complex Surgery
    AHPA Submits Comments to FDA on Proposed Traceability Rule
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    AOC Announces EMEA Price Increase
    Mule-Hide Products Co. Introduces Seal-Fast Liqui-Flash
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    NAMSA Acquires American Preclinical Services
    Quidel's QuickVue At-Home COVID-19 Test Earns EUA
    Memic Receives FDA Marketing Authorization for Hominis
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Fusion Pharmaceuticals Acquires IPN-1087
    Strata Oncology Unveils Strata PATH Trial
    Alimentiv Acquires McDougall Scientific
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    IT Cosmetics Supports Women’s Confidence
    Inter Parfums Reports a Strong Fourth Quarter
    Universal Engraving Announces New President
    Happi

    Latest Breaking News From Happi

    Croda International Acquires Alban Muller
    Givaudan Active Beauty Launches Omegablue
    Sozio Acquires Scentessence
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Abbott Label installs Domino K600i dual bar digital UV inkjet printer
    Crossmark turns to Eagle Systems for cold foil
    Maxcess launches Tidland PressureMax Airshaft Pressure Monitoring System
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Domtar Completes Sale of Personal Care Business
    Mitsui to Sell Chinese Nonwovens Business
    Dr. J's Disinfectant Wipes Approved for Distribution in CA
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA Approves Accufix Surgical's Accu-Joint Hemi Implant
    FDA OKs Q-Collar Device to Protect Athletes’ Brains During Head Impacts
    SeaSpine Releases Reef TO (TLIF Oblique) Interbody System
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login